Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1938 1
1939 5
1940 1
1941 1
1942 1
1946 2
1947 3
1948 5
1949 2
1950 12
1951 13
1952 35
1953 21
1954 9
1955 12
1956 9
1957 22
1958 17
1959 21
1960 11
1961 13
1962 28
1963 48
1964 34
1965 42
1966 43
1967 40
1968 32
1969 40
1970 41
1971 40
1972 55
1973 60
1974 64
1975 62
1976 94
1977 84
1978 89
1979 125
1980 140
1981 169
1982 223
1983 209
1984 259
1985 294
1986 311
1987 383
1988 394
1989 428
1990 523
1991 574
1992 633
1993 752
1994 827
1995 980
1996 1115
1997 1330
1998 1483
1999 1834
2000 2162
2001 2500
2002 2988
2003 3491
2004 4168
2005 5046
2006 5803
2007 6345
2008 7425
2009 8176
2010 9255
2011 10531
2012 12080
2013 13236
2014 14833
2015 15968
2016 16982
2017 18136
2018 20189
2019 22969
2020 26622
2021 30194
2022 34440
2023 33740
2024 17949
2025 1

Text availability

Article attribute

Article type

Publication date

Search Results

321,931 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for and lu
Search for Andy Lu instead (3 results)
Prostate-Specific Membrane Antigen Radioligand Therapy Using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Schuchardt C, et al. J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887335 Free PMC article.
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I&T (0.77 vs. 0.92 Gy/GBq, P = 0.0015). ...No nephrotoxicity was observed after either (177)Lu-PSMA I&T or (177)Lu-PSMA …
Despite the longer half-life of (177)Lu-PSMA-617, the renal dose was lower for (177)Lu-PSMA-617 than for (177)Lu-PSMA I …
Preclinical Evaluation of (68)Ga- and (177)Lu-Labeled Integrin alpha(v)beta(6)-Targeting Radiotheranostic Peptides.
Ganguly T, Bauer N, Davis RA, Foster CC, Harris RE, Hausner SH, Roncali E, Tang SY, Sutcliffe JL. Ganguly T, et al. J Nucl Med. 2023 Apr;64(4):639-644. doi: 10.2967/jnumed.122.264749. Epub 2022 Oct 7. J Nucl Med. 2023. PMID: 36207137 Free article.
Biodistribution was performed for (68)Ga-1 (1 and 2 h after injection), (68)Ga-2 (2 and 4 h after injection), and (177)Lu-1 and (177)Lu-2 (1, 24, 48, and 72 h after injection). The (177)Lu-2 biodistribution data were extrapolated for human dosimetry data esti …
Biodistribution was performed for (68)Ga-1 (1 and 2 h after injection), (68)Ga-2 (2 and 4 h after injection), and (177)Lu-1 and (177) …
[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.
Hennrich U, Eder M. Hennrich U, et al. Pharmaceuticals (Basel). 2022 Oct 20;15(10):1292. doi: 10.3390/ph15101292. Pharmaceuticals (Basel). 2022. PMID: 36297404 Free PMC article. Review.
In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. ...In numerous clinical trials, the efficacy of [(177)Lu]Lu-PSMA-617 was demonstrated....
In March 2022, [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)) was approved by the FDA for the treatment of prostate cancer patients. ...I …
[(177)Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy.
Lu Q, Long Y, Gai Y, Liu Q, Jiang D, Lan X. Lu Q, et al. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2342-2352. doi: 10.1007/s00259-023-06155-x. Epub 2023 Mar 6. Eur J Nucl Med Mol Imaging. 2023. PMID: 36877233
In the radioligand therapy study, mice were randomized into 4 groups: 37 MBq [(177)Lu]Lu-PSMA-617, 18.5 MBq [(177)Lu]Lu-PSMA-617, 7.4 MBq [(177)Lu]Lu-EB-PSMA-617, and saline (control). ...SPECT/CT and biodistribution showed that tumor upt …
In the radioligand therapy study, mice were randomized into 4 groups: 37 MBq [(177)Lu]Lu-PSMA-617, 18.5 MBq [(177)Lu] …
Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy.
Zha Z, Ploessl K, Choi SR, Zhao R, Jin W, Wang R, Alexoff D, Zhu L, Kung HF. Zha Z, et al. J Med Chem. 2023 Sep 14;66(17):12602-12613. doi: 10.1021/acs.jmedchem.3c01294. Epub 2023 Sep 5. J Med Chem. 2023. PMID: 37670407
To develop hetero-bivalent agents targeting both PSMA and bone metastasis, [(177)Lu]Lu-P17-079 ([(177)Lu]Lu-1) and [(177)Lu]Lu-P17-081 ([(177)Lu]Lu-2) were prepared. In vivo biodistribution studies of [(177)Lu]Lu …
To develop hetero-bivalent agents targeting both PSMA and bone metastasis, [(177)Lu]Lu-P17-079 ([(177)Lu]Lu-1) a …
Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC.
Hänscheid H, Hartrampf PE, Schirbel A, Buck AK, Lapa C. Hänscheid H, et al. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2566-2572. doi: 10.1007/s00259-020-05177-z. Epub 2021 Jan 15. Eur J Nucl Med Mol Imaging. 2021. PMID: 33452632 Free PMC article.
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in organs and tumours after [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC were compared intraindividually in five …
It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in or …
RadioLigand Therapy with [(177)Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France.
Terroir M, Lamesa C, Krim M, Vija L, Texier JS, Cassou-Mounat T, Delord JP, Vallot D, Courbon F. Terroir M, et al. Pharmaceuticals (Basel). 2023 May 16;16(5):754. doi: 10.3390/ph16050754. Pharmaceuticals (Basel). 2023. PMID: 37242537 Free PMC article. Review.
Many malignant cells could be treated with [(177)Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pathway activation. ...We review the literature on this subject and offer a clinical illustration of compassionate use in France as a perspect …
Many malignant cells could be treated with [(177)Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pa …
Efficacy and Safety of [(177)Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literature Review.
Hertelendi M, Belguenani O, Cherfi A, Folitar I, Kollar G, Polack BD. Hertelendi M, et al. Biomedicines. 2023 Mar 27;11(4):1024. doi: 10.3390/biomedicines11041024. Biomedicines. 2023. PMID: 37189646 Free PMC article. Review.
METHODS: Studies identified in PubMed from inception to 13 May 2021 must have assessed [(177)Lu]Lu-DOTA-TATE as a single agent and reported outcome data for the specific NET types of interest. ...Safety was favorable with most adverse events mild to moderate in seve …
METHODS: Studies identified in PubMed from inception to 13 May 2021 must have assessed [(177)Lu]Lu-DOTA-TATE as a single agent …
Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.
Del Olmo-García MI, Prado-Wohlwend S, Bello P, Segura A, Merino-Torres JF. Del Olmo-García MI, et al. Cancers (Basel). 2022 Jan 24;14(3):584. doi: 10.3390/cancers14030584. Cancers (Basel). 2022. PMID: 35158852 Free PMC article. Review.
Unanswered questions remain, such as the following: Which is the correct dose and individual dosimetry? Which is the place for salvage PRRT-Lu? Whicht is the role of PRRT-Lu in the pediatric population? Which is the optimal sequencing of PRRT-Lu in advanced G …
Unanswered questions remain, such as the following: Which is the correct dose and individual dosimetry? Which is the place for salvage PRRT- …
Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review.
Manafi-Farid R, Harsini S, Saidi B, Ahmadzadehfar H, Herrmann K, Briganti A, Walz J, Beheshti M. Manafi-Farid R, et al. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4028-4041. doi: 10.1007/s00259-021-05237-y. Epub 2021 Mar 6. Eur J Nucl Med Mol Imaging. 2021. PMID: 33677734 Free PMC article. Review.
Nevertheless, approximately thirty percent of patients do not respond to [(177)Lu]Lu-PSMA RLT. Here, we only reviewed and reported the evaluated factors and their impact on survival or biochemical response to treatment to have an overview of the potentialprognostic …
Nevertheless, approximately thirty percent of patients do not respond to [(177)Lu]Lu-PSMA RLT. Here, we only reviewed and repo …
321,931 results
You have reached the last available page of results. Please see the User Guide for more information.